The Evolving Evidence-Based And Guideline-Supported Role For Nanoliposomal Topoisomerase Inhibitors In Metastatic Pancreatic Adenocarcinoma

The Evolving Evidence-Based And Guideline-Supported Role For Nanoliposomal Topoisomerase Inhibitors In Metastatic Pancreatic Adenocarcinoma


Published

November 29, 2017

Created by

CMEducation Resources symposium

Related Presenters

Andrea Wang-Gillam, MD, PhD

Andrea Wang-Gillam, MD, PhD

Associate Professor of Medicine
Washington University School of Medicine
Clinical Director, Gastrointestinal Oncology Program
Siteman Cancer Center
St. Louis, MO